Methods of using interleukin 2 to enhance HIV-specific immune responses

AIDS Research and Human Retroviruses

Volumn 18, Issue 4, 2002, Pages 289-293

  Xu, Jianqing ^a,b   Whitman, Lucia ^a,b   Lori, Franco ^a,b   Lisziewicz, Julianna ^a,b   Battle, Toni ^a  

^a Research Institute for Genetic and Human Therapy   (United States)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD8 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 2; PERFORIN; VIRUS ANTIGEN; VIRUS VACCINE;

ARTICLE; CELL ACTIVATION; CELL COUNT; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; MONONUCLEAR CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN INDUCTION; T LYMPHOCYTE; VACCINATION; VIRUS LOAD; VIRUS REPLICATION;

ADJUVANTS, IMMUNOLOGIC; FLOW CYTOMETRY; HIV; HIV INFECTIONS; HUMANS; IMMUNITY, CELLULAR; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; T-LYMPHOCYTES; VIRAL LOAD;

EID: 0036201808     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922202753472865     Document Type: Article

References (14)

1. Immunological changes in peripheral blood and in lymphoid tissue after treatment of HIV-infected subjects with highly active anti-retroviral therapy (HAART) or HAART + IL-2
2. Efficacy of low-dose subcutaneous interleukin-2 to treat advanced human immunodeficiency virus type 1 in persons with ≤250/μl CD4 T cells and undetectable plasma virus load
3. + T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy
4. Reemergence of HIV after stopping therapy
5. Levels of human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy
6. IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases
7. Induction of HIV-1-specific T cell responses by administration of cytokines in late-stage patients receiving highly active anti-retroviral therapy
8. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination
9. Either B7 costimulation or IL-2 can elicit generation of primary alloreactive CTL
10. Quantitation of HIV-1 specific cytotoxic T lymphocytes and plasma load of viral RNA
11. Levels of human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy
12. Perforin is not co-expressed with granzyme A within cytotoxic granules in CD8 T lymphocytes present in lymphoid tissue during chronic HIV infection
13. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression
14. Control of SIV rebound through structured treatment interruptions during early infection